

**Supplemental Table S3.** Summary of TEAEs (Safety Analysis Set, Month 9 Final Analysis)

TEAE	Placebo (n=33)	Romosozumab 210 mg SC QM (n=34)
All TEAEs	16 (48.5)	12 (35.3)
Most frequent TEAEs ( $\geq 2$ patients in any group)		
Back pain	2 (6.1)	1 (2.9)
Nasopharyngitis	2 (6.1)	1 (2.9)
Lumbar spinal stenosis	2 (6.1)	0
TEAEs leading to treatment discontinuation	0	0
Serious TEAEs	2 (6.1)	0
Pulmonary tuberculosis <sup>a</sup>	1 (3.0)	0
Femur fracture <sup>a</sup>	1 (3.0)	0
Lumbar spinal stenosis	1 (3.0)	0
TEAEs leading to death	0	0
TEAEs of interest		
Hypocalcemia	0	0
Injection site reaction	0	0
Hypersensitivity	1 (3.0)	1 (2.9)
Cancer	0	0
Osteoarthritis	0	1 (2.9)
Hyperostosis	2 (6.1)	0
Atypical femoral fracture <sup>b</sup>	0	0
Osteonecrosis of the jaw <sup>b</sup>	0	0
Positively adjudicated serious cardiovascular events <sup>c</sup>	0	0

Values are expressed as number (%).

TEAE, treatment-emergent adverse event; SC, subcutaneous; QM, once monthly.

<sup>a</sup>Reported in the same patient; <sup>b</sup>Only includes events adjudicated positive by an independent adjudication committee; <sup>c</sup>No serious TEAEs met the criteria for cardiovascular adjudication.